Cargando…

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Yau, Kevin, Dharia, Atit, Alrowiyti, Ibrahim, Cherney, David Z.I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751670/ https://www.ncbi.nlm.nih.gov/pubmed/36531882 http://dx.doi.org/10.1016/j.ekir.2022.08.016

Ejemplares similares

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Letter Regarding “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
por: Noel, J. Ariana, et al.
Publicado: (2022)

SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
por: Kalay, Zeynepgul, et al.
Publicado: (2022)

Preventing CKD in Developed Countries
por: Luyckx, Valerie A., et al.
Publicado: (2019)

DAPA-CKD: The Beginning of a New Era in Renal Protection
por: Cherney, David Z.I., et al.
Publicado: (2021)

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
por: Thomas, Merlin C, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
por: Bernardi, Marco, et al.
Publicado: (2023)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis
por: Li, Ning, et al.
Publicado: (2022)

SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
por: Mavrakanas, Thomas A., et al.
Publicado: (2023)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
por: Spatola, Leonardo, et al.
Publicado: (2017)

SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
por: Hosokawa, Yusei, et al.
Publicado: (2020)

Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022)

PSUN172 Prescribing SGLT-2 Inhibitors and GLP-1 Agonists in Primary Care: Improving Rates of Guideline-Concordant Practice
por: Schuetz, Samantha, et al.
Publicado: (2022)

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

Tubuloglomerular Feedback in Renal Glucosuria: Mimicking Long-term SGLT-2 Inhibitor Therapy
por: Neuwirt, Hannes, et al.
Publicado: (2019)

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
por: Liu, Hongyan, et al.
Publicado: (2021)

Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022)

Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Knowledge and practice of community pharmacists towards SGLT2 inhibitors
por: Alqudah, Abdelrahim, et al.
Publicado: (2022)

Obesity Indices and the Risk of CKD
por: Tsuboi, Nobuo
Publicado: (2021)

A Review of Residual Kidney Function in Peritoneal Dialysis Patients
por: Alrowiyti, Ibrahim Mohammed, et al.
Publicado: (2023)

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

Diuretics, SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review
por: van Poelgeest, Eveline P., et al.
Publicado: (2023)

Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?
por: Cupisti, Adamasco, et al.
Publicado: (2020)

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
por: Gomez-Peralta, Fernando, et al.
Publicado: (2017)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

Toric intraocular lenses: Expanding indications and preoperative and surgical considerations to improve outcomes
por: Singh, Vivek Mahendrapratap, et al.
Publicado: (2022)

Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors
por: Klopfenstein, Mitchell, et al.
Publicado: (2015)

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
por: Wilding, John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8gnsiqrmtr962p8lre9sob8337